Advice
in the absence of a submission from the holder of the marketing authorisation:
naltrexone / bupropion (Mysimba®) is not recommended for use within NHSScotland.
Indication under review: As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of
• ≥ 30 kg/m² (obese), or
• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice192KB (PDF)
Medicine details
- Medicine name:
- naltrexone bupropion (Mysimba)
- SMC ID:
- SMC2086
- Indication:
- As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of • ≥ 30 kg/m² (obese), or • ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)
- Pharmaceutical company
- Orexigen Therapeutics Ireland Limited (1)
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 May 2018